25 May 2013
Keywords: eli, lilly, vertex, restructure, hep, deal, longer
Article | 06 January 2003
Eli Lilly will no longer participate with Vertex Pharmaceuticals onthe development of a hepatitis C virus drug, VX-950, and will ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
6 January 2003
13 January 2003
24 May 2013
© 2013 thepharmaletter.com